ReviewThe world journal of men's health2019
Obesity and Erectile Dysfunction: From Bench to Clinical Implication.
Review in The world journal of men's health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review.Andrology · 2023Pooled it
- Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis.Reviews in endocrine & metabolic disorders · 2020Pooled it
- Association between frailty index and erectile dysfunction: A cross-sectional study using NHANES 2001 to 2004 data.Medicine · 2026Article
- GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation.EClinicalMedicine · 2026Article
- Erectile dysfunction, type 2 diabetes, and cardiovascular disease: a narrative review and insights from a global real-world cohort analysis.Frontiers in clinical diabetes and healthcare · 2026Review
- Article
- The Influence of Laparscopic Sleeve Gastrectomy on Male Erectile Function among Morbid Obese Patients: an Observational Study.Obesity surgery · 2026Observational
- Glycemic control and body mass index (BMI) as risk factors for erectile dysfunction among Saudi men with diabetes: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- Impact of Obesity, Smoking, and Alcohol on Erectile Dysfunction: A Cross-Sectional Study of Lebanese Men.Cureus · 2025Article
- Erectile dysfunction among the young male population: A cross-sectional study.The Journal of international medical research · 2025Article
- Review
- Association between the C-reactive protein-triglyceride glucose index and erectile dysfunction in US males: results from NHANES 2001-2004.International journal of impotence research · 2025Article
- Potential utility of the triglyceride-glucose index as a predictor of erectile dysfunction and its severity: a cross-sectional, case-control study.Scientific reports · 2025Article
- Association between different insulin resistance surrogates and erectile dysfunction in non-diabetic men: a large population-based study.BMC public health · 2025Article
- Study on the Chemical Composition, Biological Activity, and Mechanism of Intervention in Erectile Dysfunction of Healthy Snow Lotus Wine.Food science & nutrition · 2025Article
- Erectile Dysfunction and Oxidative Stress: A Narrative Review.International journal of molecular sciences · 2025Review
- Association between serum albumin levels and erectile dysfunction in American Adults: A cross-sectional study from NHANES 2001-2004.PloS one · 2025Article
- Associated Factors for Erectile Dysfunction Occurrence in Patients with Coronary Artery Disease: A Cross-sectional Study.Iranian journal of medical sciences · 2025Article
- Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Associations between metabolic syndrome and erectile dysfunction: evidence from the NHANES 2001-2004.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, concomitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.